Osseous effects caused by Imatinib (IM) in Pediatric Patients with Chronic Myeloid Leukemia (CML).

Objective: To investigate alteration of body height, BMI, and bone metabolism in a pediatric CML cohort on upfront IM treatment. Methods: During therapy standard deviation scores (SDS) of body height, body weight, urine and serum were collected in 3-month (mo) intervals. Results: 27/111 prepubertal pts (age: < 10 y; 14 ♂/13 ♀), 46 pts pubertal pts (age: 10 – 14 y; 25 ♂/21 ♀), and 38 postpubertal pts (age: > 15 y; 24 ♂/14 ♀) on IM (mean: 16 mo; median 12 mo; range: 0 – 103 mo) showed – compared to mean height SDS at diagnosis – a mean decrease of 0.45 SDS/y and increase in BMI of 0.34 SDS/y in the total cohort du…